Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
Topic overview
Randomized trial of 105 pediatric neuroblastoma patients compared MIBG alone versus combination regimens with vincristine/irinotecan or vorinostat. MIBG plus vorinostat achieved highest response rate (32%) with manageable toxicity, while vincristine/irinotecan added no benefit and increased adverse events.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. GlobalCastMD Medical Library. 2022-01-24. https://library.globalcastmd.com/article/4810
Comments